Riskpilot← Back to searchSign inGet full accessTEBU-BIO ApS
APSActiveCVR 10156920Jernbanegade 23Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20032 employees
Revenue 2024
DKK 1,1M
-30% vs 2023
EBITDA margin
-4.2%
-131% vs 2023
Equity ratio
31.8%
Financial strength
Net profit 2024
DKK -61K
-185% vs 2023
| Revenue | DKK 1,1M | -30% |
| EBITDA | DKK -46K | -131% |
| Net profit | DKK -61K | -185% |
| Total assets | DKK 1,3M | -7% |
| Equity | DKK 401K | -13% |
| Employees | 2 | — |
Legal name
TEBU-BIO ApS
CVR number
10156920
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
17. december 2003
Share capital
DKK 125.000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen.
Company purpose
Selskabets formål er markedsføring af og handel med produkter og tjenesteydelser til anvendelse inden for biotek- og medicinalforskning samt al virksomhed, som efter direktionens skøn er beslægtet hermed.
Address
Jernbanegade 23
Phone
+4533434343
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1.170 | 1.499 | 1.122 | 1.578 | 1.098 |
| Staff expenses | -555 | -499 | -789 | -1.430 | -1.144 |
| EBITDA | 615 | 1.000 | 332 | 148 | -46 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 615 | 1.000 | 332 | 148 | -46 |
| Net financials | -10 | -24 | -53 | -57 | -31 |
| Profit before tax | 605 | 976 | 279 | 91 | -77 |
| Tax | 133 | 216 | 61 | 20 | -17 |
| Net profit | 472 | 761 | 218 | 71 | -61 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1.593 | 1.623 | 1.260 | 1.357 | 1.262 |
| Equity | 683 | 923 | 391 | 462 | 401 |
| Long-term debt | 62 | 0 | 0 | 0 | 0 |
| Short-term debt | 848 | 699 | 869 | 895 | 861 |
| Total debt | 910 | 699 | 869 | 895 | 861 |
EBITDA margin
-4.2%
This company
15.8%
Market median
-127% vs market
20202024
Equity ratio
31.8%
This company
38.2%
Market median
+17% vs market
20202024
Return on equity
-15.1%
This company
18.4%
Market median
-182% vs market
20202024
Net profit margin
-5.5%
This company
8.1%
Market median
-168% vs market
20202024
Asset turnover
0.87×
This company
1.12×
Market median
+22% vs market
20202024
Debt / equity
2.14×
This company
0.62×
Market median
-245% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
Dv Management | Management | 2004 |
| Former (2) | ||
CS Management | Management | 2003 – 2004 |
| Audit | 2003 – 2004 | |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2004 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TEBU-BIO ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Caroline Sundorph Pontoppidan | Management | 0 companies |
| GRANT THORNTON, STATSAUTORISERET REVISIONSAKTIESELSKAB | Audit | 0 companies |
| Donald van Dijk | Management | 0 companies |